trending Market Intelligence /marketintelligence/en/news-insights/trending/px_n0wh247t79huobmg_qa2 content esgSubNav
In This List

Neon Therapeutics plans $115M IPO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Neon Therapeutics plans $115M IPO

Neon Therapeutics Inc. intends to file for an IPO of up to $115 million.

The company will list on the Nasdaq Global Market under the ticker NTGN.

The Cambridge, Mass.-based biotechnology company develops therapies that target neoantigens — abnormal proteins produced by cancer cells — and personalized T cell therapies. The company has a strategic collaboration with CRISPR Therapeutics AG.

Oppenheimer & Co. is the lead manager for the transaction. Bank of America Merrill Lynch, Mizuho Securities and Morgan Stanley serve as joint book-running managers.